If you have not already registered, then visit our registration page.
Evidence-Based Long-Term Treatment of Bipolar II Disorder
Trisha Suppes, M.D., Ph.D., and Ellen B. Dennehy, Ph.D.
Bipolar II disorder is a distinct, lifelong mental illness that affects at least 1.5 million people in the United States, is associated with a high incidence of comorbidity, and ends with completed suicide in 10% to 15% of diagnosed individuals. Bipolar II disorder is characterized by at least 1 major depressive episode with 1 or more hypomanic episodes, as opposed to manic or mixed episodes. While it is expected that there may be similarities in approaches to managing patients with bipolar I and bipolar II disorders, data suggest differential patient responses to pharmacologic treatments, supporting the need for research specifically in patients with bipolar II disorder. Despite the prevalence and severity of the disorder, a well-developed scientific database informing long-term treatment choices for bipolar II disorder as an illness differing from bipolar I disorder and major depressive disorder is virtually absent. A review of the limited and sometimes contradictory information stresses that more research is needed into prophylactic and maintenance treatment of bipolar II disorder.
(J Clin Psychiatry 2002;63[suppl 10]:29–33)
From the Department of Psychiatry, Bipolar Disorder Clinic and Research Program, University of Texas Southwestern Medical Center, Dallas.
Presented at the symposium "Long-Term Use of Mood Stabilizers in Bipolar Disorder," which was held January 24–25, 2002, in San Antonio, Tex., and supported by an unrestricted educational grant from GlaxoSmithKline.
Corresponding author and reprints: Trisha Suppes, M.D., Ph.D., Department of Psychiatry, Bipolar Disorder Clinic and Research Program, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9070 (e-mail: email@example.com).